張文麗,講師，藥劑學博士，碩士生導師。2011年畢業(yè)于中國藥科大學藥劑學專業(yè)，留校任教至今，2012年12月至2014年3月赴新西蘭奧克蘭大學藥學院進修博士后。主持“國家自然科學基金”（1項），“國家教育部博士點基金”（1項），“江蘇省自然科學基金”（1項），作為骨干成員參與國家國際科技合作專項項目1項，國家自然科學基金項目4項，“國家重大新藥創(chuàng)制平臺”項目。近年來在Journal of Controlled Release, Biomaterials, Pharmerceutical Research, International Journal of Pharmaceutics等國外藥劑學雜志發(fā)表SCI論文20多篇，其中以一作發(fā)表的論文累積影響因子達30分以上，并發(fā)表國內(nèi)外會議論文4篇，授權(quán)發(fā)明專利1項。主要從事抗癌藥物靶向傳輸和新型智能釋藥系統(tǒng)的研究。

代表性論文：

1)Wenli Zhang, Guangji Wang, Esther See, John P. Shaw, Bruce C. Baguley, Jianping Liu, Satya Amirapu, Zimei Wu. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation. J. Control. Release. 2015, 203: 161-169.
2)Zhang W, Wang G, Falconer JR, Baguley BC, Shaw JP, Liu J, Xu H, See E, Sun J, Aa J, Wu Z. Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug. Pharm. Res. 2015, 32(4): 1451-1461.
3)Wenli Zhang, Ji Wang, Junting Jia, Liang Chen, Zimei Wu, Jianping Liu. A Simple Method to Extract Whole Apolipoproteins for the Preparation of Discoidal Recombined High Density Lipoproteins as Bionic Nanocarriers for Drug Delivery. Journal of Pharmacy & Pharmaceutical Sciences. 2015,18(2): 184-198.
4)Hongxiang Yan, Jin Li, Zhenghua Li, Wenli Zhang*, Jianping Liu*. Tanshinone IIA-loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation. European Journal of Pharmaceutical Sciences. 2015, 76:156-164. (*co-corresponding author)
5)Hongliang He,  Mengyuan Zhang,  Lisha Liu, Shuangshuang ZhangJianping Liu*, Wenli Zhang*. Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein. Pharmaceutical Research. 2015 (*co-corresponding author), 
6)See E#, Zhang W#, Liu J, Svirskis D, Baguley BC, Shaw JP, Wang G, Wu Z. Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. Int. J. Pharm. 2014, 473 (1–2): 528–535.(#co-first author)
7)Wenli Zhang#, Hongliang He#, Jianping Liu, Ji Wang, Suyang Zhang, Shuangshuang Zhang, Zimei Wu. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins. Biomaterials. 2013, 34(1): 306-19.(#co-first author)
8)Zhang W, Li J, Liu J, Wu Z, Xu Y, Wang J. Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in foam cell model and pharmacokinetics in rabbits. Pharmazie, 2012, 67(4): 324-330.
9)Wenli Zhang, Yan Xiao, Jianping Liu, Zimei Wu, Xiao Gu, Yiming Xu, Hui Lu. Structure and remodeling  behavior  of  drug-loaded  high  density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int. J. Pharm.  2011, 419: 314-321.
10)Zhang WL, Gu X, Hui Bai, Ruhui Yang, Chendong Dong, Jianping Liu. Nanostructured lipid carriers constituted from high-densiy lipoprotein components for delivery of a lipophilic cardiovascular drug. Int. J. Pharm. 2010, 391: 313-321.
11)Wenli Zhang, Jianping Liu, Suchun Li, Mengyuan Chen, Huan Liu. Preparation and evaluation of stealth Tashinone IIA-loaded solid lipid nanoparticles: Influence of Poloxamer 188 coating on phagocytic uptake. J. Microencapsul. 2008, 25(3): 203-209.

聯(lián)系方式：025-83271293,zwllz@163.com